REPROS THERAPEUTICS INC.

Form 8-K June 11, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

Current Report Filed Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2010

Repros Therapeutics Inc. (Exact name of registrant as specified in its charter)

Delaware 001-15281 76-0233274 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.)

2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)

(281) 719-3400 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

Item 8.01 Other Events.

On June 11, 2010, Repros Therapeutics Inc. (the "Company") issued a press release titled "FDA Lifts Full Clinical Hold on Repros' Proellex®." A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number 99.1

Description

Press Release dated June 11, 2010

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repros Therapeutics Inc.

Date: June 11, 2010 By: /s/ Joseph S. Podolski

Joseph S. Podolski

President and Chief Executive

Officer

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

EXHIBIT INDEX

Exhib it

Number Description

99.1 Press Release dated June 11, 2010